spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Charles River Laboratories Announces New Tumor Model Compendium

Charles River

The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 21, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) recently announced the launch of its new online Tumor Model Compendium web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumor models based on specific molecular and histological properties, accompanied by selected patient information.

Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research. The collection includes tumor models from a wide range of tumor subtypes for both in vivo and in vitro oncology research, including patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models. These resources allow researchers to easily identify the most appropriate tumor models, leading to a more targeted study design from the start, saving time and money on the path to the clinic.

Dedication to Immuno-oncology

The most recent Compendium update expands existing content to include human leukocyte antigen (HLA) subtyping data. As the immuno-oncology industry shifts toward increasingly more personalized therapies, the availability of HLA data helps researchers understand and control immune system variability, leading to increased study efficacy and efficiency.

The Compendium is just one example of Charles River’s commitment to developing a robust offering of immuno-oncology services. In January 2018, the Company announced its acquisition of KWS BioTest, adding significant expertise in immunology to its existing portfolio.

In Vitro
Oncology Services


Additionally, the Compendium now includes new molecular data for a large proportion of its proprietary and commercial cell lines, making it a valuable resource for in vitro oncology research. In vitro oncology has emerged as an industry standard for early toxicity and patient identification, allowing researchers to test the efficacy of compound in a rapid, reliable, and cost-effective way.

The Company has also partnered with OcellO and InSphero AG to leverage 3D cell culture technology with its existing in vitro oncology platforms. Charles River has more than 450 well-characterized, proprietary PDXs in its portfolio, which represent all major tumor histotypes, and provide extensive background and characterization for oncology research. To learn more about Charles River’s oncology research capabilities, visit www.criver.com.

Approved Quotes

“The oncology field is rapidly changing and expanding, making it critically important for researchers to be as efficient as possible. If we can save researchers any amount of time in getting their studies started, that ultimately leads to safe and effective treatments being delivered to patients faster.” –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River “In oncology, there is a massive amount of information to sort through. The Tumor Model Compendium makes the data easily accessible and simple to digest, and allows scientists to select the most relevant data for their research.” –Aidan Synnott, Executive Director, Discovery Oncology, Charles River About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
phone 1.781.222.6000
web www.criver.com
email 251 Ballardvale St., Wilmington, MA 01887
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Automated testing of pharmaceutical packaging

Test-result reproducibility and traceability are essential when testing pharmaceutical packaging and medical products. Zwick has developed a robotic testing system for automated testing applications ranging from childproof bottles (withpress-and-turn caps) to auto-injectors and insulin pens; tests on these include determination of the release force. As well as increasing specimen throughput and reducing per-specimen costs, automation reduces operator influence, while releasing laboratory staff for more demanding activities in line with their skills and qualifications.
More info >>


White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

Industry Events

PPMA SHOW 2018

25-27 September 2018, NEC, Birmingham, UK

The UK’s leading production line event is celebrating its 30th Anniversary. Taking place at the NEC, Birmingham from 25-27 September 2018, the exhibition showcases the latest processing and packaging machinery. Attended by thousands of manufacturers of food, pharmaceuticals and FMCG as well as contract packers and more.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement